Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases.
Stock is 

SEC Filings

Filing date Form Description Filing Group View
SC 13G/A

An amendment to the SC 13G filing

Other
View HTML
SC 13G/A

An amendment to the SC 13G filing

Other
View HTML
8-K

Report of unscheduled material events or corporate event

Current Reports
View HTML
PREM14A

A preliminary proxy statement relating to a merger or acquisition

Mergers & Acquisitions
View HTML
8-K

Report of unscheduled material events or corporate event

Current Reports
View HTML
3

Initial filing by director officer or owner of more than ten percent.

3,4,5
View HTML
DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
View HTML
8-K

Report of unscheduled material events or corporate event

Current Reports
View HTML
DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
View HTML
DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
View HTML